A notable finding is that audiences are split on whether they see more pharma ads in 2025 compared to 2024. Nearly half of ...

In today’s Pharmaceutical Executive Daily, Eli Lilly reports positive topline Phase III results for retatrutide, the FDA expands Amgen’s Uplizna label into generalized myasthenia gravis subtypes, and ...

Entasis’ Nuzolvence and GSK’s Blujepa are the first antibiotic approvals in gonorrhoea in over 30 years in the US.

The appeal of these diverse careers often lies in the different types of impact they enable. A PhD can teach more than ...

We found that one-third of pharmaceutical companies proactively released the launch price of their medications between 2022 and 2024, and another third released them reactively. Smaller public ...

Shares in argenx fell after the pharmaceutical company said it would stop late-stage trials for an experimental drug to treat thyroid eye disease due to lack of efficacy. In European afternoon trading ...

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

Based on research and analysis of the global microecology market, as well as the evaluation of relevant companies in the ...

Rising uncompensated care, escalating cybersecurity and climate risks, and major shifts in the 340B and pharmacy benefit manager landscapes are prompting health systems to rethink how they deliver and ...

Global CRISPR Technology Market OverviewThe global CRISPR technology market is poised for strong expansion, projected to grow at a robust CAGR of approximately 16% over the next five years. This ...

Companies say the EU’s deregulation efforts are insufficient against Trump's “carrot-and-stick” strategy of pairing generous US tax incentives with a punitive 15% tariff on imports from the EU.

In 2023, Japan's market size for Paroxysmal Nocturnal Hemoglobinuria therapeutics was around USD 88.5 million, with expectations of growth throughout the forecast period (2024-2034). Projections ...